Piekarz RL - Search Results

1

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.

Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, Jaffe ES, Ling A, Turner M, Peer CJ, Figg WD, Steinberg SM, Smith S, Joske D, Lewis I, Hutchins L, Craig M, Fojo AT, Wright JJ, Bates SE. Piekarz RL, et al. Blood. 2011 Jun 2;117(22):5827-34. doi: 10.1182/blood-2010-10-312603. Epub 2011 Feb 25. Blood. 2011. PMID: 21355097 Free PMC article. Clinical Trial.

2

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report.

Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L, Kingma DM, Turner ML, Altemus R, Bates SE. Piekarz RL, et al. Blood. 2001 Nov 1;98(9):2865-8. doi: 10.1182/blood.v98.9.2865. Blood. 2001. PMID: 11675364 Free article. Clinical Trial.

3

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE. Sandor V, et al. Among authors: piekarz rl. Clin Cancer Res. 2002 Mar;8(3):718-28. Clin Cancer Res. 2002. PMID: 11895901 Clinical Trial.

4

T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance.

Piekarz RL, Robey RW, Zhan Z, Kayastha G, Sayah A, Abdeldaim AH, Torrico S, Bates SE. Piekarz RL, et al. Blood. 2004 Jun 15;103(12):4636-43. doi: 10.1182/blood-2003-09-3068. Epub 2004 Mar 2. Blood. 2004. PMID: 14996704 Free article.

5

A review of depsipeptide and other histone deacetylase inhibitors in clinical trials.

Piekarz R, Bates S. Piekarz R, et al. Curr Pharm Des. 2004;10(19):2289-98. doi: 10.2174/1381612043383980. Curr Pharm Des. 2004. PMID: 15279609 Review.

6

Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometry.

Hwang K, Piekarz RL, Bates SE, Figg WD, Sparreboom A. Hwang K, et al. Among authors: piekarz rl. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Sep 25;809(1):81-6. doi: 10.1016/j.jchromb.2004.06.007. J Chromatogr B Analyt Technol Biomed Life Sci. 2004. PMID: 15282096

7

Effect of a histone deacetylase inhibitor on human cardiac mass.

Shizukuda Y, Piekarz RL, Bates SE, Sachdev V, Finkel T, Rosing DR. Shizukuda Y, et al. Among authors: piekarz rl. Cardiovasc Drugs Ther. 2005 Jan;19(1):89-90. doi: 10.1007/s10557-005-6901-7. Cardiovasc Drugs Ther. 2005. PMID: 15883760 No abstract available.

8

Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176).

Robey RW, Zhan Z, Piekarz RL, Kayastha GL, Fojo T, Bates SE. Robey RW, et al. Among authors: piekarz rl. Clin Cancer Res. 2006 Mar 1;12(5):1547-55. doi: 10.1158/1078-0432.CCR-05-1423. Clin Cancer Res. 2006. PMID: 16533780 Clinical Trial.

9

Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma.

Piekarz RL, Frye AR, Wright JJ, Steinberg SM, Liewehr DJ, Rosing DR, Sachdev V, Fojo T, Bates SE. Piekarz RL, et al. Clin Cancer Res. 2006 Jun 15;12(12):3762-73. doi: 10.1158/1078-0432.CCR-05-2095. Clin Cancer Res. 2006. PMID: 16778104 Clinical Trial.

10

Challenges of evaluating the cardiac effects of anticancer agents.

Bates SE, Rosing DR, Fojo T, Piekarz RL. Bates SE, et al. Among authors: piekarz rl. Clin Cancer Res. 2006 Jul 1;12(13):3871-4. doi: 10.1158/1078-0432.CCR-06-1017. Clin Cancer Res. 2006. PMID: 16818679 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

81 results

Search Page